Cetuximab in Non-small-cell Lung Cancer

Overview

Journal Transl Lung Cancer Res

Date 2015 Mar 26

PMID 25806155

Citations 9

Authors

Robert Pirker

Martin Filipits

Affiliations

Soon will be listed here.

Abstract

Cetuximab is a chimeric monoclonal antibody that is directed towards the epidermal growth factor receptor (EGFR). It has been evaluated in combination with first-line chemotherapy in several phase II and two phase III trials in patients with advanced NSCLC. The phase III FLEX trial demonstrated improved survival for cetuximab combined with cisplatin plus vinorelbine compared to chemotherapy alone. The BMS099 trial failed to show a significant improvement in progression-free survival but resulted in a hazard ratio for death similar to the one seen in the FLEX trial. A meta-analysis of four randomized trials confirmed the efficacy of cetuximab when added to chemotherapy. EGFR expression levels based on an immunohistochemistry score have recently been shown to predict benefit from cetuximab in the FLEX trial. In patients with high EGFR expression, patients had prolonged survival when treated with chemotherapy plus cetuximab compared to chemotherapy alone. In patients with low EGFR expression, outcome was not different between the two treatment arms. Thus platinum-based chemotherapy combined with cetuximab represents a new treatment option for patients with advanced NSCLC and high EGFR expression in their tumors. Cetuximab is also evaluated in combination with chemoradiotherapy in patients with stage III NSCLC.

Citing Articles

Dual Potential of Cetuximab Conjugated Hydroxyapatite Zirconium Nanoparticle as Nanocarrier for Radioenhancer in X-Ray Dynamic Therapy and Lu-based Radioimmunotherapy of Lung Cancer.

Kurniawan A, Mahendra I, Rizaludin A, Utama M, Lesmana R, Ayuningtyas F Nanotheranostics. 2025; 9(1):82-94.

PMID: 40078313 PMC: 11898717. DOI: 10.7150/ntno.101699.

Next-generation sequencing as a valuable tool for mutational spectrum in advanced-stage NSCLC patients.

Iurca I, Isakescu E, Pop L, Budisan L, Pirlog R, Harangus A Med Pharm Rep. 2024; 97(3):298-307.

PMID: 39234458 PMC: 11370849. DOI: 10.15386/mpr-2763.

Cutting-Edge Therapies for Lung Cancer.

Laah A, Chiou S Cells. 2024; 13(5.

PMID: 38474400 PMC: 10930724. DOI: 10.3390/cells13050436.

Targeting Cell Signaling Pathways in Lung Cancer by Bioactive Phytocompounds.

Choudhary N, Bawari S, Burcher J, Sinha D, Tewari D, Bishayee A Cancers (Basel). 2023; 15(15).

PMID: 37568796 PMC: 10417502. DOI: 10.3390/cancers15153980.

Multicellular Effects of STAT3 in Non-small Cell Lung Cancer: Mechanistic Insights and Therapeutic Opportunities.

Parakh S, Ernst M, Poh A Cancers (Basel). 2021; 13(24).

PMID: 34944848 PMC: 8699548. DOI: 10.3390/cancers13246228.

References

Ardizzoni A, Boni L, Tiseo M, Fossella F, Schiller J, Paesmans M . Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007; 99(11):847-57. DOI: 10.1093/jnci/djk196. View

Robert F, Blumenschein G, Herbst R, Fossella F, Tseng J, Saleh M . Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol. 2005; 23(36):9089-96. DOI: 10.1200/JCO.2004.00.1438. View

Govindan R, Bogart J, Stinchcombe T, Wang X, Hodgson L, Kratzke R . Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. J Clin Oncol. 2011; 29(23):3120-5. PMC: 3157978. DOI: 10.1200/JCO.2010.33.4979. View

Rosell R, Robinet G, Szczesna A, Ramlau R, Constenla M, Mennecier B . Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol. 2007; 19(2):362-9. DOI: 10.1093/annonc/mdm474. View

Pirker R, Filipits M . Monoclonal antibodies against EGFR in non-small cell lung cancer. Crit Rev Oncol Hematol. 2010; 80(1):1-9. DOI: 10.1016/j.critrevonc.2010.10.008. View

Pfister D, Johnson D, Azzoli C, Sause W, Smith T, Baker Jr S . American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol. 2003; 22(2):330-53. DOI: 10.1200/JCO.2004.09.053. View

Schiller J, von Pawel J, Schutt P, Ansari R, Thomas M, Saleh M . Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer. J Thorac Oncol. 2010; 5(12):1977-85. DOI: 10.1097/JTO.0b013e3181f4a5c9. View

Pirker R, Filipits M . Targeted therapies in lung cancer. Curr Pharm Des. 2009; 15(2):188-206. DOI: 10.2174/138161209787002915. View

Butts C, Bodkin D, Middleman E, Englund C, Ellison D, Alam Y . Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol. 2007; 25(36):5777-84. DOI: 10.1200/JCO.2007.13.0856. View

10.

Pirker R, Pereira J, Szczesna A, von Pawel J, Krzakowski M, Ramlau R . Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009; 373(9674):1525-31. DOI: 10.1016/S0140-6736(09)60569-9. View

11.

Belani C, Schreeder M, Steis R, Guidice R, Marsland T, Butler E . Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study. Cancer. 2008; 113(9):2512-7. DOI: 10.1002/cncr.23902. View

12.

Thienelt C, Bunn Jr P, Hanna N, Rosenberg A, Needle M, Long M . Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol. 2005; 23(34):8786-93. DOI: 10.1200/JCO.2005.03.1997. View

13.

Kollmannsberger C, Schittenhelm M, Honecker F, Tillner J, Weber D, Oechsle K . A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 2006; 17(6):1007-13. DOI: 10.1093/annonc/mdl042. View

14.

Khambata-Ford S, Harbison C, Hart L, Awad M, Xu L, Horak C . Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2010; 28(6):918-27. DOI: 10.1200/JCO.2009.25.2890. View

15.

Kurai J, Chikumi H, Hashimoto K, Yamaguchi K, Yamasaki A, Sako T . Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res. 2007; 13(5):1552-61. DOI: 10.1158/1078-0432.CCR-06-1726. View

16.

Felip E, Gridelli C, Baas P, Rosell R, Stahel R . Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Ann Oncol. 2011; 22(7):1507-1519. DOI: 10.1093/annonc/mdr150. View

17.

Herbst R, Kelly K, Chansky K, Mack P, Franklin W, Hirsch F . Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342. J Clin Oncol. 2010; 28(31):4747-54. PMC: 3020704. DOI: 10.1200/JCO.2009.27.9356. View

18.

Pirker R, Minar W, Filipits M . Integrating epidermal growth factor receptor-targeted therapies into platinum-based chemotherapy regimens for newly diagnosed non-small-cell lung cancer. Clin Lung Cancer. 2009; 9 Suppl 3:S109-15. DOI: 10.3816/CLC.2008.s.016. View

19.

Hirsch F, Herbst R, Olsen C, Chansky K, Crowley J, Kelly K . Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol. 2008; 26(20):3351-7. PMC: 3368372. DOI: 10.1200/JCO.2007.14.0111. View

20.

Lynch T, Patel T, Dreisbach L, McCleod M, Heim W, Hermann R . Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol. 2010; 28(6):911-7. DOI: 10.1200/JCO.2009.21.9618. View